Novo Nordisk and Pfizer have revised their bids for Metsera, the obesity drug developer said on Tuesday. Novo's revised offer ...
This offer highlights Novo Nordisk’s commitment to investing in the US and interest in continuing to grow the scale of its US ...
Investor's Business Daily on MSN
Pfizer Hikes Earnings Outlook Even As Third-Quarter Sales Decline
Pfizer stock dipped early Tuesday despite hiking its 2025 profit guidance, as third-quarter sales and earnings both toppled ...
Pfizer and Novo Nordisk have both offered to sweeten their bids for the US obesity biotech Metsera, in the latest development ...
Pfizer et Novo Nordisk se livrent une guerre de milliards pour se positionner sur le marché florissant des médicaments ...
Pfizer reported a drop in third-quarter profits Tuesday as lower sales of Covid-19 products more than offset gains in other ...
Gold Spot US Dollar, Pfizer Inc, US Dollar Index Futures, S&P 500 Futures. Read 's Market Analysis on Investing.com ...
Pfizer has increased its annual profit forecast and reported higher-than-expected profits for the third quarter amid a legal ...
Pfizer raised its full-year profit forecast for the second consecutive quarter and reported a higher-than-expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback